Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Up to $21.25

Calliditas Therapeutics AB (publ) (NASDAQ:CALT - Get Free Report)'s share price gapped up before the market opened on Thursday . The stock had previously closed at $21.25, but opened at $22.00. Calliditas Therapeutics AB (publ) shares last traded at $22.48, with a volume of 1,043 shares.

Analyst Ratings Changes

Separately, HC Wainwright restated a "buy" rating and set a $50.00 price target on shares of Calliditas Therapeutics AB (publ) in a research note on Thursday, February 22nd.

Calliditas Therapeutics AB (publ) Trading Up 3.9 %

The business has a 50 day simple moving average of $21.53 and a 200-day simple moving average of $20.43. The company has a current ratio of 3.13, a quick ratio of 3.08 and a debt-to-equity ratio of 2.89. The stock has a market capitalization of $657.76 million, a price-to-earnings ratio of -13.46 and a beta of 1.50.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT - Get Free Report) last issued its quarterly earnings results on Wednesday, February 21st. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.09) by $0.02. Calliditas Therapeutics AB (publ) had a negative return on equity of 104.47% and a negative net margin of 38.72%. The firm had revenue of $42.45 million for the quarter, compared to analyst estimates of $36.24 million. During the same period last year, the company earned ($0.01) EPS. On average, equities analysts predict that Calliditas Therapeutics AB will post 0.29 earnings per share for the current year.

Hedge Funds Weigh In On Calliditas Therapeutics AB (publ)

Several hedge funds and other institutional investors have recently modified their holdings of the company. Optiver Holding B.V. acquired a new position in shares of Calliditas Therapeutics AB (publ) in the 4th quarter valued at about $25,000. Deutsche Bank AG raised its holdings in shares of Calliditas Therapeutics AB (publ) by 26.5% during the 1st quarter. Deutsche Bank AG now owns 90,509 shares of the company's stock valued at $2,170,000 after buying an additional 18,978 shares during the period. Jane Street Group LLC raised its holdings in shares of Calliditas Therapeutics AB (publ) by 7.6% during the 3rd quarter. Jane Street Group LLC now owns 12,491 shares of the company's stock valued at $191,000 after buying an additional 886 shares during the period. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Calliditas Therapeutics AB (publ) by 1,270.2% during the 3rd quarter. Tower Research Capital LLC TRC now owns 3,357 shares of the company's stock valued at $51,000 after buying an additional 3,112 shares during the period. 2.83% of the stock is owned by institutional investors and hedge funds.

About Calliditas Therapeutics AB (publ)

Calliditas Therapeutics AB (publ), a commercial-stage specialty pharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.